Patents by Inventor Donna Johnstone

Donna Johnstone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-?1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agent
    Patent number: 7820679
    Abstract: The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: October 26, 2010
    Assignee: AstraZeneca AB
    Inventors: David William Tonge, Sian Tomiko Taylor, Francis Thomas Boyle, Andrew Mark Hughes, Donna Johnstone, Marianne Bernice Ashford, Nigel Charles Barrass
  • Combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent
    Publication number: 20100035896
    Abstract: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent.
    Type: Application
    Filed: June 12, 2009
    Publication date: February 11, 2010
    Applicant: ASTRAZENECA AB
    Inventors: John Curwen, Andrew Hughes, Donna Johnstone, Francis Thomas Boyle, Gwen Boyle
  • Combination of N-(3-Methoxy-5-Methylpyrazin-2-Yl)-2-(4-[1,3,4-Oxadiazol-2-Yl]Phenyl)Pyridine-3-Sulphonamide and an Anti-Mitotic Cytotoxic Agent
    Publication number: 20080076780
    Abstract: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent.
    Type: Application
    Filed: November 23, 2005
    Publication date: March 27, 2008
    Applicant: ASTRAZENECA AB
    Inventors: John Curwen, Andrew Hughes, Donna Johnstone, Francis Boyle, Gwen Boyle
  • Therapeutic treatment
    Publication number: 20060122180
    Abstract: A combination, comprising an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and an EGFR TKI, or a pharmaceutically acceptable salt thereof is described.
    Type: Application
    Filed: October 7, 2003
    Publication date: June 8, 2006
    Inventors: Francis Boyle, Jon Curwen, Neil Gallagher, Ursula Hancox, Andrew Hughes, Donna Johnstone, Sian Taylor, David Tonge
  • N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
    Publication number: 20060094729
    Abstract: The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.
    Type: Application
    Filed: August 20, 2003
    Publication date: May 4, 2006
    Applicant: AStraZeneca AB
    Inventors: David Tonge, Sian Tayer, Francis Boyle, Andrew Hughes, Donna Johnstone, Marianne Ashford, Nigel Barrass
  • 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
    Publication number: 20060009512
    Abstract: The use of a 5-HT1B/1D receptor agonist in the treatment or prevention of headache that results from administering an endothelin receptor antagonist; and the combination, comprising an endothelin receptor antagonist and a 5-HT1B/1D receptor agonist is described.
    Type: Application
    Filed: October 6, 2003
    Publication date: January 12, 2006
    Applicant: AstraZeneca AB
    Inventors: Jon Curwen, Andrew Hughes, Donna Johnstone, Clive Morris